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Most of the matrix metalloproteinases (MMP) are not
expressed in normal intact skin but they are upregu-
lated in in£amed or diseased skin. The recently cloned
MMP-19 is one of the few MMP members that are also
expressed in healthy epidermis. In this study, we found
that MMP-19 is generally coexpressed with cytokeratin
14 that is con¢ned to keratinocytes of the stratum ba-
sale. MMP-19 was also detected in hair follicles, sebac-
eous glands, and eccrine sweat glands. Its expression,
however, changed in cutaneous diseases exhibiting in-
creased alternations of epidermal proliferation, such as
psoriasis, eczema, and tinea. In the a¡ected area,
MMP-19 was also found in suprabasal and spinous epi-
dermal layers.We also studied the regulation of MMP-
19 expression at the protein level, as well as by using a
promoter assay. The constitutive expression of MMP-19
was upregulated with phorbol myristate acetate and
downregulated with retinoic acid and dexamethasone.
Tumor necrosis factor-a, interleukin (IL)-6,TGF-b, IL-
15, IL-8, and RANTES as well as the bacterial com-
pounds lipopolysaccharide and lipoteichoic acid did
not show any profound e¡ect in HaCaT cells. In con-
trast, type IV and type I collagens upregulated MMP-19
signi¢cantly. The dysregulation of MMP-19 expression
in epidermis suggests its possible involvement in the
perpetuation of cutaneous infections and proliferative
disorders such as psoriasis. Key words: mmp/regulation/
psoraisis/epidermis. J Invest Dermatol 121:989 ^996, 2003
M
atrix metalloproteinases (MMP) are responsible
for the degradation of various components of
the extracellular matrix (ECM) as well as for
processing of cell-surface receptors and adhesion
molecules. A strict regulation of these enzymes
represents an important mechanism in homeostasis. Most MMP
are upregulated after damage to the epidermis or in diseased skin
(Okada et al, 1997; Madlener, 1998; Parks et al, 1998).Together with
serine proteases, MMP are involved in wound healing and re-
building of the epidermal barrier that protects the body against
pathogens (Lund et al, 1999). Accordingly, it has been shown that
wound healing was delayed in mice treated with an MMP-speci-
¢c inhibitor. Also, mice de¢cient for stromelysin 1 (MMP-3)
(Agren et al, 2001) exhibited a retarded wound healing, although
reepithelialization appeared normal (Bullard et al, 1999). In con-
trast, the overexpression of MMP-1 in a transgenic mouse model
also led to a delay in wound healing (Di Colandrea et al, 1998).
During wound healing and in in£ammatory processes, MMP
are responsible for the processing of basal membrane components
such as collagen type IV, laminin 5, nidogen, and proteins of the
provisional wound bed, for example, ¢brin, ¢bronectin, and col-
lagen type I (Parks et al, 1998). Another aspect that emerged more
recently is the involvement of MMP in the regulation of local
homeostasis by the release of growth factors and cytokines from
their extracellular stores, their processing, or the processing of
their receptors. Thus, TGF-b is activated by MT1-MMP and
MMP-9. MMP-9 can also increase the activity of interleukin
(IL)-8 through an N-terminal processing that enhances the pro-
liferation of various cells in the skin (Van den Steen et al, 2000;
Mu et al, 2002).
Microbial infections as well as psoriasis are accompanied by an
in£ammation and a dysregulation of epidermal proliferation and
di¡erentiation. The regulation and the role of most of the MMP
in cutaneous infections have not yet been delineated, although
MMP produced in the skin are able to degrade virtually all
ECM components. Increased degradation of ECM proteins could
therefore facilitate the dissemination of pathogens. Thus, human
bronchial epithelial cells upregulate both gelatinases upon stimu-
lation with lipopolysaccharide (LPS). In addition, chlamydial
HSP60 positively regulates the expression of gelatinases in
macrophages (Yao et al, 1996; Kol et al, 1998). Furthermore, phos-
pholipase C, a putative virulence factor of several pathogenic bac-
teria, appears to increase the expression of gelatinase B and
stromelysin 1 in epithelial cells (Firth et al, 1997).
In this study, we have characterized the epidermal expression
of the recently cloned MMP-19 (Cossins et al, 1996; PendaŁ s et al,
1997; Sedlacek et al, 1998). This study also complements the study
of Impola et al (2003), who reported the expression of MMP-19 in
malignant epidermal tumors and various wounds.We found that
MMP-19 was typically expressed in basal keratinocytes of the
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intact healthy epidermis but was dysregulated in psoriasis as well
as in eczema and tinea. Generally, its expression correlated with
that of cytokeratin 14 and can be downregulated by retinoic acid
(RA) and dexamethasone (Dex). A signi¢cant upregulation
of MMP-19 appears upon contact of keratinocytes with type I
collagen.
MATERIALS AND METHODS
Antibody preparation For immunostaining, a new monoclonal
antibody was prepared. Its immunoreactivity was compared with the
a⁄nity-puri¢ed polyclonal rabbit anti-MMP-19 antibodies designated
anti-Pep21. These latter antibodies were prepared as described previously
by immunization of rabbits with the KHL-coupled peptide and recognize
a unique 21-amino-acid peptide derived from the hinge region (Sedlacek
et al, 1998). The monoclonal antibody CK8/4 was prepared by immunization
of a mouse with the full-length human MMP-19. The selected antibody
CK8/4 recognizes speci¢cally the propeptide domain, as determined
by immunoblotting of MMP-19 constructs representing its individual
domains and by ELISA against the prodomain-derived peptide NH2-
LQKPLEGSNNFKPDITEALRAFQEASEL. Further analysis with synthe-
tic peptides has shown that the CK8/4 does not cross-react with other
known MMP. The antibody was puri¢ed from culture supernatants using
protein A^Sepharose (Pharmacia, Germany).
Cell culture and transfection The HaCaT keratinocyte cell line was
generously provided by N. Fusenig (DKFZ, Heidelberg, Germany). Cells
were maintained at 371C in a humidi¢ed atmosphere of 5% CO2 in
Dulbecco’s modi¢ed Eagle’s medium (PAA, Linz, Austria) supplemented
with 10% fetal calf serum, 50 units per mL penicillin, and 50 mg per mL
streptomycin. For the regulation studies, cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium with 0.5% fetal calf serum and stimulated with
the following compounds at given concentrations: tumor necrosis factor-a
(TNF-a; 1.0 and 10 ng/mL; donated by D. Adam, Kiel, Germany), IL-15
(20 ng/mL; donated by R. Rˇckert, Borstel, Germany), IL-8 (10, 50, and
100 ng/mL; Sigma Aldrich), native regulated on activation normal T cells
expressed and secreted (RANTES, 10 and 100 ng/mL, donated by J.-M.
Schr˛der Kiel, Germany), IL-6 (0.1, 1.0, and 10 pg/mL, donated by S.
Rose-John, Kiel, Germany), LPS, and lipoteichoic acid (LTA; 1, 5, and 10
mg/mL; Sigma Aldrich). Type I and type IV collagen (BD Biosciences,
Bedford, MA) were coated in concentrations 5 and 10 mg per cm2,
respectively, on a microtiter plate.
The full-length cDNA of human MMP-19 was subcloned into pIRES2-
EGFP (Clontech, Paolo Alto, CA), hereafter referred to as pIRES-
MMP19WT. HaCaT keratinocytes were transfected with the FuGENE 6
transfection reagent according to the manufacturer’s instructions (Roche,
Mannheim, Germany), and stable cell lines were selected in 0.6 mg per
mL G418.
Foreskin for isolation of primary keratinocytes was donated by R. Paus
(Hamburg, Germany). These keratinocytes were cultured for 48 h in K-
SFM medium (Gibco, Invitrogen Corp., Carlsbad, CA) on monomeric
type I collagen medium containing either 0.05 or 1.2 mM CaCl2 or 0.05
mM CaCl2 plus 20 ng per mL TGF-a (Promocell GmbH, Heidelberg,
Germany).
Promoter activity The regulation of the promoter of MMP-19 was
studied using the dual-luciferase assay (Promega, Madison,WI) and with
the vector construct containing the 1898-bp stretch of the 50 -£anking
region (^1898/LUC) as described previously (Mueller et al, 2000). Brie£y,
5104 HaCaT cells per well cells were transfected with ^1898/LUC
construct using the Fugene 6 (Roche) in the serum-free K-SFM medium
(Gibco, Invitrogen Corp.) containing 0.03 mM CaCl2. Twenty-four hours
after each transfection assay, the media were replaced with serum-free K-
SFM medium (Gibco, Invitrogen Corp.) containing 0.03 mM CaCl2 and
one of the following compounds: Dex (10, 1, and 0,1 mmol; Sigma
Aldrich), RA (10, 1, and 0.1 mmol; Sigma Aldrich), phorbol myristate
acetate (PMA, 0.1 mM; Sigma Aldrich), IL-6 (1 ng/mL), IL-8 (200 ng/mL),
TNF-a (100 ng/mL), and TGF-b (10 ng/mL). Cells were cotransfected with
pRL-TK renilla luciferase vector (Promega) as an internal control, as
described above. Forty-eight hours after transfection, the cells were
washed and lyzed, and luminescence was measured according to the
manufacturer’s manual (Promega) using a single-sample luminometer
(TD/20, Turner Design, Sunnyvale, CA). All assays were performed in
duplicate in three separate experiments. The means of these duplicates
were taken to obtain the relative luciferase activity, which is expressed in
relative light units as de¢ned by the ratio of ¢re£y to renilla luciferase
activity multiplied by the factor 104. Data are presented as means7SEM
and show the percentage of relative light units change against the control
(without the stimulatory/inhibitory compound). Results were analyzed
using one-way ANOVAwith Tukey’s multiple comparison post test.
Immunostaining Tissue specimens embedded in para⁄n were sectioned
to 3-mm thickness, depara⁄nized, and incubated in 3% H2O2 to block
endogenous peroxidase activity. Antigen retrieval was performed by
treating sections with 10 mM citric acid, pH 6.0 at 901C for 30 min. After
being washed in 5 mM Tris^HCl bu¡er containing 150 mM NaCl, pH 7.3
(TBS), sections were digested with 0.1% trypsin inTBS for 10 min at 371C
and then blocked with normal serum, which was prepared from the species
in which the secondary antibody was produced. To detect MMP-19, both
the monoclonal anti-MMP-19 antibody CK8/4 and the polyclonal a⁄nity-
puri¢ed rabbit anti-pep21 were used. Basal keratinocytes were identi¢ed
with monoclonal anti-cytokeratin 14 antibody (ICN, Irvine, CA). Bound
antibodies were detected using the Vectastain ABC Elite kit (Vector
Laboratories, Burlingame, CA) following the manufacturer’s instructions.
Peroxidase activity was detected using 3-amino-9-ethylcarbazole as a
chromogenic substrate (Vector Laboratories). Sections were counterstained
with hematoxylin. The speci¢city of the staining was proved with an IgG1
control antibody (not shown).
For immuno£uorescent detection, human skin was embedded in Jung
tissue freezing medium (Leica Instruments, Nussloch, Germany), snap-
frozen in liquid nitrogen, and cut to a thickness of 3 mm. The sections
were air-dried and ¢xed in acetone for 30 s, after which they were
blocked with Powerblock (Biogenex, San Ramon, CA) and incubated
with the primary antibody (CK8/4 diluted to 1:100) in phosphate-bu¡ered
saline/Triton X-100 (0.1%) containing 3% bovine serum albumin for 2 h
at room temperature. Bound antibodies were detected with Alexa 488-
conjugated goat anti-mouse IgG antibody (Molecular Probes, Eugene,
OR). The sections were ¢nally mounted using EUKITT (O. Kindler
GmbH & Co, Freiburg, Germany). Images were taken from 8 to 12
representative sections of a tissue sample and were captured by a video
camera (Sony, Japan) mounted on an Olympus BX-500 £uorescent
microscope. Images were processed with the Analysis Soft Imaging
system (Lakewood, CA).
Immunoblotting and gelatin zymography HaCaT cells were scraped
from the tissue culture vessel into ice-cold phosphate-bu¡ered saline,
pelleted by centrifugation, and then lyzed for 45 min on ice in 10 mM
Tris^HCl bu¡er containing 1 mM EDTA, 150 mM NaCl, 1% Triton
X-100, pH 7.5, Complete proteinase inhibitor (Roche, Germany). The
amount of protein in the samples was determined using the BCA protein
assay (Pierce, Rockford, IL). Proteins in the culture medium of HaCaTcells
were concentrated by the addition of 4 vol of ice-cold acetone. Equal
amounts of proteins were separated by SDS^PAGE, followed by
electrophoretic transfer onto a nitrocellulose membrane (Schleicher &
Schuell, Germany). Membranes were blocked with 3% milk in TNT
bu¡er containing 20 mM Tris-HCl, 500 mM NaCl, and 0.05% Tween 20,
pH 7.5. MMP-19 was detected with the following antibodies: a⁄nity-
puri¢ed polyclonal anti-MMP-19 (anti-pep21) antibodies prepared as
described, monoclonal antibody CK8/4, or polyclonal a⁄nity-puri¢ed
anti-MMP-19 (Chemicon, Temecula, CA). Staining with monoclonal
antibodies against cytokeratin 14 (Cappel/ICN, Aurora, OH) and Ki67
(Dako, Hamburg, Germany) was used to correlate the staining pattern of
MMP-19. For immunoblotting, the purchased anti-MMP19 antibodies
(Chemicon) were preferred because they better re£ected the quantitative
di¡erences than the other two antibodies.
Primary antibodies were diluted 1:1000 in 2% milk in TNT bu¡er. The
bound antibodies were detected using peroxidase-conjugated goat anti-
rabbit and anti-mouse IgG antibodies (Pierce, Rockford, IL) and the
chemiluminescence luminol reagent (Santa Cruz Biotechnology, Santa
Cruz, CA). Signals were recorded with a luminescent image analyzer
(FujiFilm,Tokyo, Japan).
For zymography, conditioned media standardized for cell number
were mixed with a nonreducing SDS sample bu¡er and loaded onto
8% polyacrylamide gels containing 1 mg per mL gelatin. After
electrophoresis, the gels were soaked in 2.5% Triton X-100 to remove the
SDS. Gelatinolytic activities were developed in 50 mM Tris-HCl bu¡er
containing 5 mM CaCl2, and 0.05% Triton X-100, pH 7.5 at 371C for 24
h. Lytic bands were visualized by staining the gels with Coomassie
brilliant blue R-250 and destaining in 10% acetic acid.
Immunoprecipitation For detection of secreted MMP-19, keratinocytes
were labeled overnight with 50 mCi per mL [35S]methionine/cysteine.
Media were collected, centrifuged to discard cellular debris, and incubated
with 50 mL per mL Pansorbin (Calbiochem, San Diego, CA) for 1 h at 41C.
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After centrifugation, antibodies against MMP-19 (Chemicon) were added
to a ¢nal concentration of 2 mg per mL, followed by overnight incubation
at 41C. After the addition of protein G^Sepharose, and an additional
incubation for 1 h at 41C, the precipitates were washed three times with
cold Tris bu¡er (10 mM Tris, 150 mM NaCl, 1 mM EDTA, and 1%
Triton X-100, pH 7.4). Precipitates were boiled in Laemmli bu¡er and
separated on 10% SDS^polyacrylamide gels under reducing conditions.
Gels were ¢xed, incubated for 30 min in Amplify £uorographic reagent
(Amersham Pharmacia Biotech, Freiburg, Germany), dried, and exposed
to X-ray ¢lms.
Clinical material Formalin-¢xed, para⁄n-embedded samples of skin
derived from 21 patients with ages ranging between 16 and 65 years were
obtained from the Department of Dermatology, University of Kiel,
Germany, with the approval of the Regional Board of the Medical Ethics
Commission. Healthy tissue was obtained from patients, aged between 16
and 25 years, undergoing surgical procedure for skin tumors. (n¼ 3). Skin
specimens included eczema (n¼ 7), tinea corporis (n¼ 7), and psoriasis
(n¼ 7). To study activation of MMP-19 in psoriatic lesions and healthy
skin, biopsies were obtained from patients with plaque type psoriasis
(n¼ 3). Biopsies from healthy skin area of the same patients were used as
controls. For immuno£uorescence staining, tissue was also obtained from
patients (n¼ 3) undergoing surgery for the removal cancerous skin. These
samples were stored in Dulbecco’s modi¢ed Eagle’s medium for 2^3 h until
their processing for cryosectioning.
RESULTS
Expression of MMP-19 in a healthy epidermis In the healthy
human skin, the staining for MMP-19 was generally restricted
to the basal epidermal layer. Suprabasal and di¡erentiated
keratinocytes did not show immunoreactivity to MMP-19
(Fig 1a,b). The expression pattern of MMP-19 correlated
with the expression of cytokeratin 14 that represents a marker
for undi¡erentiated basal keratinocytes. It appeared that the
MMP-19 expression was polarized in the basal keratinocytes:
most of the immunoreactivity was localized to the basal side of
the cells (Fig 1b). In healthy skin, dermal ¢broblasts and other
cells resident in the dermis were not stained with any of the
antibodies used in this study.
Figure1. Expression of MMP-19 in di¡erent compartments of the skin. (a,b) Using immunohistochemistry as well as immuno£uorescence, mono-
clonal antibody CK8/4 against MMP-19 exhibits immunoreactivity to the basal epidermal layer of the normal healthy human skin. (b) Normal human skin:
MMP-19 in basal keratinocytes shows polarized basolateral expression. The slightly elongated form of basal keratinocytes was due to a 3-h delay between
the surgical excision of the sample and its ¢xation. (c) Sebaceous gland. Cells of the secretory epithelium, most likely undi¡erentiated cells in the proximity
of the gland capsule, and cells in the gland duct are stained for MMP-19 (CK8/4 antibody). (d) Eccrine sweat glands. Monoclonal antibody CK 8/4 and (e)
polyclonal antibodies anti-pep21 exhibit a di¡use staining pattern of the entire duct wall as well as the basal and luminal layers. (f) MMP-19 is stained
within the terminal hair follicle and in undi¡erentiated secretory cells of sebaceous glands. (g) Cytokeratin 14 staining corresponds to the MMP-19 expres-
sion in the hair follicle and in sebaceous glands. (h, i) Cells of outer the root sheet of the hair follicle show positive immunoreactivity to anti-MMP-19
antibodies. Arrowheads depict capillaries positive for MMP-19. (j, k). MMP-19-positive endothelial and smooth muscle cells in veins and arteries can be found
in the triads in the dermis. Arrows denote MMP-19-positive blood vessels. (l, m) Capillaries, venules, and arterioles in the a¡ected area in tinea are positively
stained with anti-MMP-19 antibodies. (n) In the vein, both smooth muscle and endothelial cell are stained for MMP-19. Endothelial cells of a small lym-
phatic vessel are stained weakly (arrow). (o) Endothelial cells of a large lymphatic vessel in the a¡ected area of eczema are stained with the anti-MMP-19
antibodies anti-Pep21. Antibodies: CK8/4, a^d, f, h, j, l, n; anti-pep21, e, i, k, m, o; cytokeratin 14, g. Bars, 20 mm, b; 50 mm, a, f, g, l^n; 100 mm, c^e, h^k, o.
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Hair follicles and glands In hair follicles the anti-MMP-19
immunoreactivity was mostly found in cells within the outer
root sheet and corresponded with the cytokeratin 14 staining
(not shown). This could be seen in the transverse sections of
terminal hair follicles (Fig 1h,i) of the anagen stage. Both
antibodies used to identify MMP-19 expression showed a very
similar staining pattern in the outer root sheet. Cells in the
inner root sheet and the connective tissue sheet were stained
weakly with both antibodies. The capillaries that nourish the
connective sheet expressed MMP-19 as well. Strong immuno-
reactivity could also be seen in the section of the middle of the
terminal hair follicle of the postanagen phase (inner root sheet is
missing; Fig 1f,g). The hair follicle is surrounded by sebaceous
glands where MMP-19 was expressed by the cells of the
secretory epithelium, mostly by undi¡erentiated cells in
proximity of the gland capsule (Fig 1d,f,g). In eccrine sweat
glands, there was a di¡use staining of the entire duct wall as
well as of the basal and luminal layers. Nevertheless, the normal
eccrine glands displayed considerable variations in staining,
ranging from a negative to an intense reaction (Fig 1d,e).
Expression of MMP-19 in blood vessels In the normal
healthy skin MMP-19 was typically not expressed in endothelial
cells of larger blood vessels (not shown). Nevertheless, capillaries,
which nourish hair follicles and various glands, appeared to
express MMP-19 (Fig 1c,e,f,h, arrowheads). Endothelial cells in
lymphatic vessels were also stained with the anti-MMP-19
antibodies (Fig 1n,o). Furthermore, blood vessels in triads
that contain an artery, a vein, and a nerve, expressed MMP-19
in both endothelial cells and smooth muscle cells (Fig 1j,k).
Smooth muscle cells in the arterioles were usually stained
moderately. In the a¡ected areas of various skin diseases,
the staining for MMP-19 in blood vessels was obvious.
Especially in areas with a large in¢ltration of in£ammatory cells,
almost all capillaries, venules, and arterioles (Fig 1i,m) were
stained.
Dysregulation of MMP-19 during epidermal diseases In
eczema MMP-19 immunostaining was not con¢ned to the
stratum basale but extends to the lower to middle spinous layers
(Fig 2a). This correlated with cytokeratin 14 whose expression
was also dysregulated in the same manner (Fig 2b). Typically,
large dermal in¢ltration of in£ammatory cells were observed
beneath the area in which the epidermal expression of MMP-19
was dysregulated.
In tinea corporis an extended staining for MMP-19 was visible
in the basal and the entire spinous layers (Fig 2c). The staining
pattern of cytokeratin 14 was similar and involved the basal and
the lower half of the spinous layers (Fig 2d). Compared to the
eczema, the dysregulation of MMP-19 as well as cytokeratin 14
was not necessarily accompanied by the in¢ltration of
in£ammatory cells in the dermis.
Figure 2. Dysregulation of MMP-19 in
di¡erent epidermal diseases. (a) Eczema.
MMP-19 immunostaining extends from the
stratum basale up to the middle spinous
layers. (b) This corresponds to the expression
of cytokeratin 14. In£ammatory in¢ltrates
are present under the area with the MMP-
19 dysregulation (arrows). (c) Tinea corporis.
MMP-19 was stained within the basal and
spinous layers. (d) Cytokeratin 14 staining
pattern is similar to that of MMP-19 and in-
volves the basal as well as the lower half of
the spinous layers. (e-i) Psoriasis. (e, f) Immu-
nostaining for MMP-19 is detected in the
basal layer in rete ridges and in the arcades
but also extended to keratinocytes in the su-
prabasal layers of the rete ridges and base of
ridges. An intense staining was also identi-
¢ed in the upper spinous layers, especially
by anti-Pep21 (e). The staining for MMP-19
in the basal, suprabasal, and higher spinous
layers correlates with the expression of cyto-
keratin 14 (g). Staining for the proliferation
marker Ki67 correlates with the expression
of MMP-19 in the basal and suprabasal layers
but not in the upper spinous layers (h). (i)
Immunoblotting of MMP-19 in healthy
and psoriatic skin. Whereas monoclonal
antibody CK8/4, directed against the pro-
peptide domain, recognizes only a single
band representing the unprocessed glycosy-
lated form of MMP-19, the polyclonal anti-
pep21 (anti-hinge region) recognizes both
the processed and the unprocessed form.
Bars, 100 mm.
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In psoriasis staining with anti-MMP-19 antibodies, the
polyclonal a⁄nity-puri¢ed anti-Pep21 (Fig 2e), and the
monoclonal CK8/4 (Fig 2f) antibodies revealed obvious
expression of MMP-19 in the basal layer in the papillae (rete
ridges) and arcades (Fig 2e,f). Moreover, the staining for MMP-
19 was extended to the suprabasal layers at the rete ridges and also
irregularly to suprabasal and spinous keratinocytes in the ridges
(Fig 2e). The antibodies recognizing the hinge region of MMP-
19 (anti-Pep21; Sedlacek et al, 1998) showed a staining pattern
corresponding to that of the CK8/4 antibody, although upper
spinous layers were stained more intensively. This small
di¡erence most likely re£ects the processing of MMP-19. The
monoclonal antibody CK8/4 that are directed against the
propeptide domain cannot recognize the processed form of
MMP-19 without this domain (Mauch et al, 2002). The most
intensive staining was found in basal layers, as with the CK8/4,
and in upper spinous layers. The staining for MMP-19 in the
basal and higher spinous layers correlated with the presence of
cytokeratin 14 (Fig 2g). The staining also correlated with the
proliferation marker Ki67 in the basal and suprabasal layers of
rete ridges and also partially in the arcades. Nevertheless, no
correlation was observed in the upper spinous layers (Fig 2h).
Because the expression of MMP-19 appeared to be
dysregulated in the psoriatic lesions, we tried to elucidate
whether MMP-19 is di¡erentially processed in the diseased area.
Small biopsies from psoriatic lesions and healthy skin of the same
patient were analyzed by immunoblotting with antibodies
recognizing the propeptide domain and hinge region of MMP-
19. Thus, we were able to di¡erentiate between the processed,
probably active, and unprocessed forms of this enzyme. Using
both antibodies, we could identify the unprocessed glycosylated
form of 70 kDa. The band representing this form was
considerably weaker in the psoriatic lesions (Fig 2i) than in
healthy skin. In contrast, MMP-19 in the psoriatic lesions,
stained with anti-hinge antibodies, appeared to be converted
into a processed form (glycosylated) that seems to be
predominant and may represent active MMP-19 (Fig 2, left
panel). Thus, MMP-19 is not only upregulated in psoriatic lesions
but appears most likely in an active, processed form.
Regulation of MMP-19 in HaCaT keratinocytes Because the
expression of MMP-19 was dysregulated in the diseased areas
studied, we analyzed which compounds, including cytokines
and chemokines, in£uence the expression of MMP-19 in the cell
line HaCaT and in primary keratinocytes.We also compared the
protein expression with the activity of the MMP-19 promoter.
HaCaT cells express endogenous MMP-19 without additional
cytokine stimulation and thus resemble the basal keratinocytes
that express MMP-19 constitutively. TNF-a and IL-6 are pro-
in£ammatory cytokines that are upregulated in various pathologic
situations and are involved in wound healing, psoriasis, and
in£ammation. Both cytokines are known to upregulate several
MMP. Nevertheless, MMP-19 expression was not a¡ected either
at the protein or at the transcriptional level, as can be seen from
the promoter activity assays (Fig 3a,e). In contrast, the expression
of MMP-9 (gelatinase B) was induced byTNF-a in the HaCaT
cells as can be deduced from its increased gelatinolytic activity
(Fig 3b). IL-15, which is upregulated in the epidermis under
in£ammatory conditions and which is also able to inhibit
apoptosis in keratinocytes, has also no profound e¡ect (Fig 3a).
IL-8 and RANTES, which are both expressed in in£ammatory
sites and have powerful chemotactic capabilities, do not in£uence
MMP-19 expression at the protein level (Fig 3a,c).
Concurrently, we have also analyzed whether the bacterial
components LPS and LTA in£uence the expression of MMP-19
using immunoblotting. Neither of these seemed to signi¢cantly
a¡ect the expression of MMP-19 (Fig 3d).
Because no obvious up- or downregulation with the com-
pounds studied was observed at the protein level, we also analyzed
the regulation of the MMP-19 promoter. As in experiments at the
Figure 3. Regulation of MMP-19 in
HaCaT keratinocytes. (a) TNF-a, IL-15,
and RANTES exhibited no obvious e¡ects
on MMP-19 expression in HaCaT cells. (b)
MMP-9 is induced in the HaCaT cells by
the treatment with TNF-a. MMP-9 is de-
noted by the arrow. Lower gelatinolytic
bands originated from MMP-2. (c) IL-6
and IL-8 as well (d) LPS and LTA do not in-
£uence the expression of MMP-19. (e) Tran-
scriptional activity of the MMP-19
promoter was studied using the dual-lucifer-
ase assay. TNF-a, IL-6, IL-8, and TGF-b did
not show any profound e¡ect. The promoter
activity was signi¢cantly upregulated by
PMA and downregulated by RA and Dex.
An increase or decrease in luminescence (re-
lative light units) is shown as a percentage of
the control experiment, i.e., without stimu-
latory/inhibitory compounds. po0.05 for
comparison to the untreated control.
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protein level, TNF-a, IL-6, IL-8, and TGF-b did not show
any profound e¡ects. Nevertheless, the promoter activity was
signi¢cantly upregulated by PMA and downregulated by RA
and Dex (Fig 3e).
MMP-19 is expressed predominantly in the basal layer of
healthy epidermis but not in higher epidermal layers with di¡erenti-
ating keratinocytes. Because increased calcium concentrations lead
to the induction of keratinocyte di¡erentiation, we analyzed
the e¡ect of calcium on MMP-19 expression in primary
dermal keratinocytes. Nevertheless, neither 0.05 nor 1.2 mM
CaCl2 a¡ected MMP-19 expression in primary subcon£uent
keratinocytes. Interestingly,TGF-b, which in the HaCaT cell line
did not in£uence MMP-19, clearly upregulated MMP-19 in these
primary cells (Fig 4a).
Furthermore, we investigated whether the expression of
MMP-19 is regulated by adhesion to ECM proteins, such as type
I and type IV collagens. Plating HaCaT keratinocytes on these
collagen matrices or uncoated dishes revealed that the expression
of MMP-19 protein and mRNA was signi¢cantly induced by
type I collagen, whereas only a weak increase was observed in
cells cultured on type IV collagen (Fig 4b^d). Type I collagen
also induced the secretion of MMP-19 as increased amounts of
this protein could be immunoprecipitated from radiolabeled
keratinocytes (Fig 4b).
DISCUSSION
Although many MMP can be produced by keratinocytes, only a
few of them are expressed constitutively in normal healthy epi-
dermis (Parks et al, 1998, and publications cited therein). Here we
show that MMP-19 is constitutively expressed in the stratum ba-
sale and that its staining pattern correlates with that of cytokera-
tin 14, a marker for undi¡erentiated basal keratinocytes. Such
strong constitutive expression is unique among the MMP. Only
epilysin (MMP-28), which is phylogenetically the closest MMP
to MMP-19, shows a comparable expression in the basal layer
although it can be also found in suprabasal layers in the healthy
epidermis (Lohi et al, 2001).
The staining with anti-MMP-19 antibodies also revealed its ex-
pression in the outer root sheet of the hair follicle. MMP in the
hair follicles have not been extensively studied and there are only
fragmentary data on their expression and function in hair follicles
and glands in the skin. Nevertheless, MMP-2 and tissue inhibitor
of metalloproteinase-1 (TIMP-1) were stained strongly in anagen
tissue of the hair follicle (Yamazaki et al, 1999). MMP-9 was loca-
lized to the lower part of the inner root sheath (Henle’s layer) of
human anagen hair follicles (Jarrousse et al, 2001). Jarrousse and
colleagues (2001) also postulated that MMP-9 is important for
involution of hair follicles.
In the sebaceous glands, undi¡erentiated cells localized to the
basement membrane were stained for MMP-19. Why MMP-19
expression is con¢ned to the cells in the vicinity of the basement
membrane remains to be elucidated. On the basis of previous
studies, it could be postulated that the activity of MMP-19 is re-
quired for processing of basement membrane proteins such as la-
minin, collagen type IV, and tenascin C (Stracke et al, 2000). In
the ecrinne sweat glands, MMP-19 exhibits di¡use expression in
the entire duct wall as well as in the basal and luminal layers.
Nevertheless, the intensity of the expression varies among the in-
dividual glands.
In addition to examining MMP-19 in normal skin, we also in-
vestigated MMP-19 expression in skin disorders in which the
proliferation and di¡erentiation of keratinocytes is disturbed. In
tinea corporis as well as eczema, MMP-19 was expressed not only
in the stratum basale, as it is in the healthy epidermis, but its ex-
pression also extended to the spinous layers. The staining pattern
of MMP-19 correlated with the expression of cytokeratin 14, a
marker for basal undi¡erentiated cells.
It has been reported that MMP are also upregulated in psoriasis
that is characterized by hyperproliferation of keratinocytes, angio-
genesis, and in¢ltration of in£ammatory cells.Whereas MMP-10
and MMP-13 were reported not to be expressed in keratinocytes,
MMP-3 was detected in basal keratinocytes. In addition, MMP-
12 (metalloelastase) and MMP-9 (gelatinase B) were found in in-
£ammatory in¢ltrates. Because the expression of these MMP was
largely con¢ned to in£ammatory cells, and because TIMP-1 was
also abundant, it seems the overexpression of MMP, inhibited by
TIMP-1, is unlikely to contribute to psoriatic tissue alterations
(Suomela et al, 2001). An increase in the expression of gelatinases
MMP-2 and MMP-9 in early psoriatic lesions seemed to be ac-
companied by low levels of TIMP-1 and TIMP-2 (Feliciani et al,
1997). TIMP-2 and MMP-2 were reported to be expressed in ba-
sal and suprabasal keratinocytes. (Fleischmajer et al, 2000). The
unprocessed form of MMP-19, i.e., the form with the propeptide
domain, was identi¢ed by the monoclonal antibody CK8/4 in su-
prabasal and spinous keratinocytes in the ridges as well as irregu-
larly in rete ridges. The anti-pep21 antibodies that recognize the
hinge region, i.e., the processed as well as unprocessed forms, re-
vealed a staining corresponding to that one of CK8/4.There were
also foci with increased immunoreactivity in the higher spinous
layers. This localization of MMP-19 in spinous layers did not cor-
relate with the proliferation marker Ki67 but did correspond to
the staining of cytokeratin 6 (not shown) whose expression is up-
regulated in proliferating keratinocytes or in response to stress sti-
muli such as wounding. (Mommers et al, 2000; Wojcik et al,
2000). There was, however, a corresponding staining of Ki 67
and MMP-19 in basal and suprabasal layers in rete ridges. More-
over,TIMP-2, the strongest native inhibitor for MMP-19 was not
observed in the higher spinous layers in psoriatic lesions (Fleisch-
majer et al, 2000).
Figure 4. Adhesion of human HaCaT keratinocytes to collagens upregulates MMP-19. (a) Expression of MMP-19 in primary human keratinocytes.
K-SFM medium contained 0.05 mM CaCl2þ (C, control), 1.2 mM CaCl2þ , and 0.05 mM CaCl2þ plus 20 ng per mLTGF-a (TGF-a). (b) HaCaT keratino-
cytes were plated on type I (coll I) and type IV (coll IV) collagen and on uncoated plastic dishes (C). The upregulation was determined at protein (b) and
mRNA (c) levels. Expression of MMP-19 was considerably induced by type I collagen, whereas only a weak increase was observed in cells cultured on
collagen type IV.WB, western blotting; IP, immunoprecipitation. All immunoblots were stained with the polyclonal a⁄nity-puri¢ed anti-MMP-9 antibodies
(Chemicon).
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Both anti-MMP-19 antibodies showed comparable staining in
basal and suprabasal keratinocytes in the psoriatic lesions. The
anti-Pep21 antibodies revealed a slightly more pronounced stain-
ing in the upper spinous layers. This variation results most likely
from processing of MMP-19 into active forms, which partially
di¡use within the ECM and are not identi¢able with the anti-
body CK8/4.
To examine whether MMP-19 is di¡erentially activated in
psoriatic lesions, we compared the expression pattern of MMP-
19 using two antibodies recognizing either the propeptide do-
main (CK8/4) or the hinge region (anti-pep21). Both antibodies
used revealed that a band representing the unprocessed glycosy-
lated form of MMP-19 is weaker in psoriatic lesions than in
healthy skin. Staining with anti-pep21 antibodies recognizing
both the unprocessed and the N-terminally processed forms of
MMP-19 clearly showed that the reduced intensity of the band
was due to increased processing of this MMP-19 form and that
the processed glycosylated form was predominant in the psoriatic
lesions. Because MMP-19 showed a distinct expression in the
psoriatic lesions, we suggest that MMP-19 contributes to the per-
petuation of this disease.
Because in eczema and psoriasis abundant in£ammatory in¢l-
trates were found at the a¡ected sites, and because the bacterial
and fungal infections trigger diseases such as tinea and folicullitis,
we analyzed whether in£ammatory cytokines, chemokines, and
bacterial components in£uence the expression of MMP-19 in Ha-
CaTcells. The HaCaT keratinocytes express MMP-19 without ad-
ditional stimulation and thus resemble basal keratinocytes in vivo.
Surprisingly,TNF-a, IL-6, and IL-15 as well as chemokines IL-8
and RANTES did not exhibit any obvious in£uence on the ex-
pression of MMP-19 in HaCaT cells. It has already been shown
that TNF-a generally initiates the expression of various MMP
and we have also seen an increase in the gelatinolytic activity of
MMP-9 induced by this cytokine. The constitutive expression of
MMP-19 and almost no transcriptional regulation resembles the
regulation of MMP-2. In addition, MMP-19 appears to be clearly
upregulated by TGF-b at the protein level in primary keratino-
cytes. Similarly, the transcription of MMP-2 is upregulated by
TGF-b, although other MMP are suppressed by this cytokine
(Brown et al, 1990; Overall et al, 1991).
RANTES, which was reported to upregulate MMP-19 in
macrophages (Locati et al, 2002), did not appear to a¡ect the ex-
pression of MMP-19 in HaCaT cells. Because bacterial products
may also be involved in the regulation of proteolytic enzymes,
we tested the e¡ect of LPS and LTA and supernatants from Pseu-
domonas aeruginosa on MMP-19 expression.
To further support the data on the regulation of MMP-19 in
keratinocytes, we have employed the promoter luciferase assay
using the MMP-19 promoter containing 1.9 kb of the 50 -£anking
region. As in immunoblotting, TNF-a, IL-6, and IL-8 did not
show any profound e¡ects on the promoter. Furthermore, TGF-
b, which clearly upregulated MMP-19 expression in primary ker-
atinocytes, did not a¡ect the promoter. This discrepancy could
mirror either di¡erences between primary cells and the immorta-
lized HaCaT cell line or di¡erential e¡ects of TGF-b on post-
transcriptional events such as stabilization of the mRNA or facil-
itating its transport and translation into protein (Dodge et al, 1990,
and the references therein).
The promoter activity was signi¢cantly upregulated by PMA.
The data on regulation of the MMP-19 promoter with PMA and
TGF-b also correspond with data of Impola et al (2003) who ana-
lyzed this using real-time quantitative PCR. Interestingly, RA as
well as Dex exhibited a profound downregulation of the promo-
ter. RA, vitamins with pleiotropic function, are used to treat
psoriasis since they inhibit cellular proliferation and in£amma-
tion (Nagpal and Chandraratna, 2000; Kuenzli and Saurat, 2001).
Thus, MMP-19 in psoriatic lesions would consequently also be
inhibited by this treatment. The glucocorticoid Dex is also
known to inhibit the expression and activity of other MMP
(McGuire-Goldring et al, 1983; Sadowski and Steinmeyer, 2001).
In contrast to the cytokines and chemokines tested in this
study, the expression of MMP-19 was in£uenced by contact to
type I and type IVcollagens.Whereas HaCaT keratinocytes plated
on type I collagen considerably upregulated the expression of
MMP-19, type IV collagen caused only a weak increase of
MMP-19. Therefore, it seems that the MMP-19 could be upregu-
lated in response to changes in ECM. Such regulation may play a
role in many cutaneous diseases in which keratinocytes are ex-
posed to type I collagen and its fragments that are absent in the
intact epidermis.
In summary, MMP-19 appears to have a unique expression pat-
tern in the skin. It is constitutively expressed in basal keratino-
cytes in healthy skin as well as in HaCaT cells. Its expression
extends to the suprabasal and spinous layers in diseased skin. Such
an expression pattern correlates with that of cytokeratin 14. Be-
cause MMP-19 was found to be coexpressed with cytokeratin 14
throughout the study, it was evident that its expression is asso-
ciated with the undi¡erentiated basal or proliferating keratino-
cytes. Moreover, the ratio between unprocessed and processed
forms of MMP-19 in psoriatic lesions was skewed to the pro-
cessed form, which most likely represents an active enzyme.
Based on the data reported here, it could be suggested that
MMP-19 is involved in propagation of cutaneous diseases and
with its capacity to degrade several components of the basement
membrane may enable pathogens to cross the disrupted epider-
mal barrier and disseminate in the host.
We thank Elsbeth Schulz for excellent technical assistance.We are grateful to R. Paus
for providing us with skin for isolation of primary keratinocytes.We thank also S.
Rose-John and Lee Shaw for critical reading of the manuscript.This work was sup-
ported by grants from DFG to R.S. (SE 878/2-1 and SFB 617/A8) and to E.P.
(SFB 415/B2 and SFB 617/A7).
REFERENCES
Agren MS, Mirastschijski U, Karlsmark T, Saarialho-Kere UK: Topical synthetic in-
hibitor of matrix metalloproteinases delays epidermal regeneration of human
wounds. Exp Dermatol 10:337^348, 2001
Brown PD, Levy AT, Margulies IM, et al: Independent expression and cellular pro-
cessing of Mr 72,000 type IV collagenase and interstitial collagenase in human
tumorigenic cell lines. Cancer Res 50:6184^6191, 1990
Bullard KM, Lund L, Mudgett J, et al: Impaired wound contraction in stromelysin-1-
de¢cient mice. Ann Surg 230:260^265, 1999
Cossins J, Dudgeon TJ, Catlin G, Gearing AJH, Clements JM: Identi¢cation of
MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys
Res Commun 228:494^498, 1996
Di Colandrea T, Wang L, Wille J, D’Armiento J, Chada KK: Epidermal expression
of collagenase delays wound-healing in transgenic mice. J Invest Dermatol
111:1029^1033, 1998
Dodge GR, Kovalszky I, Hassell JR, Iozzo RV: Transforming growth factor beta
alters the expression of heparan sulfate proteoglycan in human colon carcino-
ma cells. J Biol Chem 265:18023^18029, 1990
Feliciani C, Vitullo P, D’orazi G, et al: The 72-kDa and the 92-kDa gelatinases, but
not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic
lesions. Exp Dermatol 6:321^327, 1997
Firth JD, Putnins EE, Larjava H, Uitto VJ: Bacterial phospholipase C upregulates
matrix metalloproteinase expression by cultured epithelial cells. Infect Immun
65:4931^4936, 1997
Fleischmajer R, Kuroda K, Hazan R, et al: Basement membrane alterations in psor-
iasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor
TIMP-2. J Invest Dermatol 115:771^777, 2000
Impola U,Toriseva M, Suomela S, et al: Matrix metalloproteinase-19 is expressed by
proliferating epithelium but disappears with neoplastic dedi¡erentiation. Int J
Cancer 103:709^716, 2003
Jarrousse F, Boisnic S, Branchet MC, et al: Identi¢cation of clustered cells in human
hair follicle responsible for MMP-9 gelatinolytic activity: Consequences for
the regulation of hair growth. Int J Dermatol 40:385^392, 2001
Kol A, Sukhova GK, Lichtman AH, Libby P: Chlamydial heat shock protein 60
localizes in human atheroma and regulates macrophage tumor necrosis factor-
a and matrix metalloproteinase expression. Circulation 98:300^307, 1998
Kuenzli S, Saurat JH: Retinoids for the treatment of psoriasis: Outlook for the
future. Curr Opin Invest Drugs 2:625^630, 2001
MMP-19 EXPRESSION IN NORMAL AND DISEASED SKIN 995VOL. 121, NO. 5 NOVEMBER 2003
Locati M, Deuschle U, Massardi ML, et al: Analysis of the gene expression pro¢le
activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide
in human monocytes 1. J Immunol 168:3557^3562, 2002
Lohi J,Wilson CL, Roby JD, Parks WC: Epilysin: A novel muman matrix metallo-
proteinase (MMP-27) expressed in testis and keratinocytes and in response to
injury. J Biol Chem 276:10134^10144, 2001
Lund LR, Romer J, Bugge TH, et al: Functional overlap between two classes of ma-
trix-degrading proteases in wound healing. EMBO J 18:4645^4656, 1999
Madlener M: Di¡erential expression of matrix metalloproteinases and their physio-
logical inhibitors in acute murine skin wounds. Arch Dermatol Res 290
(Suppl):24^29, 1998
Mauch S, Kolb C, Kolb B, Sadowski T, Sedlacek R: Matrix Metalloproteinase-19 is
expressed in myeloid cells in an adhesion-dependent manner and associates
with the cell surface. J Immunol 168:1244^1251, 2002
McGuire-Goldring MK, Murphy G, Gowen M, et al: E¡ects of retinol and dexa-
methasone on cytokine-mediated control of metalloproteinases and their inhi-
bitors by human articular chondrocytes and synovial cells in culture. Biochim
Biophys Acta 763:129^139, 1983
Mommers JM, van Rossum MM, van Erp PE, van De Kerkhof PC: Changes in
keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of
spreading psoriasis. Dermatology 201:15^20, 2000
Mu D, Cambier S, Fjellbirkeland L, et al: The integrin alpha (v) beta8 mediates
epithelial homeostasis through MT1-MMP-dependent activation of TGF-
beta1. J Cell Biol 157:493^507, 2002
Mueller M, Mauch S, Sedlacek R: Structure of the human MMP-19 gene. Gene
252:27^37, 2000
Nagpal S, Chandraratna RA: Recent developments in receptor-selective retinoids.
Curr Pharm Des 6:919^931, 2000
Okada A,Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P: Expression of matrix
metalloproteinases during rat skin wound healing: Evidence that membrane
type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.
J Cell Biol 137:67^77, 1997
Overall CM,Wrana JL, Sodek J: Transcriptional and post-transcriptional regulation
of 72-KDA gelantinase/type IV collagenase by transforming growth factor-
beta 1 in human ¢broblasts. Comparisons with collagenase and tissue inhibitor
of matrix metalloproteinase gene expression. J Biol Chem 266:14064^14071, 1991
Parks WC, Sudbeck BD, Doyl GR, Saariahlo-Kere U: Matrix metalloproteinases in
tissue repair in matrix metalloproteinases. In: Biology of Extracellular Matrix
Series. San Diego: Academic Press, 1998; p 263^298
PendaŁ s AM, Knuper V, Puente XS, et al: Identi¢cation and characterization of
a novel human matrix metalloproteinase with unique structural char-
acteristics, chromosomal location, and tissue distribution. J Biol Chem
272:4281^4286, 1997
Sadowski T, Steinmeyer J: E¡ects of tetracyclines on the production of matrix me-
talloproteinases and plasminogen activators as well as of their natural inhibi-
tors, tissue inhibitor of metalloproteinases-1 and plasminogen activator
inhibitor-1. In£amm Res 50:175^182, 2001
Sedlacek R, Mauch S, Kolb B, et al: Matrix metalloproteinase MMP-19 (RASI-1) is
expressed on the surface of activated peripheral blood mononuclear cells and is
detected as an autoantigen in rheumatoid arthritis. Immunobiology 198:408^423,
1998
Stracke JO, Hutton M, Stewart M, et al: Biochemical characterization of the
catalytic domain of human matrix metalloproteinase 19: Evidence for a role
as a potent basement membrane degrading enzyme. J Biol Chem 275:14809^
14816, 2000
Suomela S, Kariniemi AL, Snellman E, Saarialho-Kere U: Metalloelastase (MMP-
12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and
-3, are expressed in psoriatic lesions. Exp Dermatol 10:175^183, 2001
Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil
gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing,
whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES
and MCP-2 intact. Blood 96:2673^2681, 2000
Wojcik SM, Bundman DS, Roop DR: Delayed wound healing in keratin 6a knock-
out mice. Mol Cell Biol 20:5248^5255, 2000
Yamazaki M,Tsuboi R, LeeYR, Ishidoh K, Mitsui S, Ogawa H: Hair cycle-depen-
dent expression of hepatocyte growth factor (HGF) activator, other protei-
nases, and proteinase inhibitors correlates with the expression of HGF in rat
hair follicles. J Invest Dermatol Symp ProcThe 4:312^315, 1999
Yao PM, Buhler JM, d’Ortho PM: Expression of matrix metalloproteinase gelati-
nases A and B by cultured epithelial cells from human bronchial explants.
J Biol Chem 28:15580^15589, 1996
996 SADOWSKI ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
